Company: SHPH
Filing Date: 2025-03-19
Form Type: PRE 14A
Source: 0001493152-25-010886
Chunk: 15

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-19
Form: PRE 14A
Chunk 15
---
 (NEOs), as disclosed in this proxy statement.                                                                    
 The                                                                                                                                 
 Board of Directors therefore recommends you vote “FOR” the resolution that the compensation paid to the Company’s                   
 NEOs, as disclosed pursuant to Item 402 of Regulation S-K, including the Executive Compensation, compensation tables, and narrative 
 discussions to be hereby APPROVED.                                                                                                  |

Approval on an advisory basis of the compensation of our NEOs is an ordinary resolution and must receive the affirmative vote of a majority of the votes cast in person or by proxy at the 2025 Annual Meeting in order to be approved.

THE TEXT OF THE RESOLUTION IN RESPECT OF PROPOSAL 3 IS AS FOLLOWS:

“RESOLVED, that the Company’s stockholders approve, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in this proxy statement in the section entitled “Executive Compensation,” including the compensation tables and narrative discussions set forth therein.”

ADVISORY VOTE ONLY

This vote is advisory, and therefore not binding on the Company, the Compensation Committee, or the Board of Directors. However, the Compensation Committee will consider the outcome of the vote when considering future executive compensation arrangements. Abstentions and broker non-votes will have no effect on the vote on this proposal.

Executive Compensation

Summary Compensation Table

The table below summarizes all compensation awarded to, earned by, or paid to our Chief Executive Officer and Chief Financial Officer and certain of our other executive officers for 2024 and 2023.

| 14 |

<div align='center'>SUMMARY COMPENSATION TABLE</div>

| Name                                
 and principal position              |     | Year |      |     | Salary 
 ($)    |         |     | Bonus 
 ($)   |         |     | Stock  
 Awards 
 ($)    |         |     | Option 
 Awards 
 ($)    |   |     | Non-Equity                      
 Incentive Plan Compensation ($) |   |     | Nonqualified                   
 Deferred Compensation Earnings 
 ($)                            |   |     | All                
 Other Compensation 
 ($)                |   |     | Total 
 ($)   |         |
| Anatoly Dritschilo M.D., CEO        |     |      | 2024 |     |        | 274,000 |     |       |       - |     |        |       - |     |        | - |     |                                 | - |     |                                | - |     |                    | - |